Published online before print May 15, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




* Vaccine Research and Development Center, National Health Research Institutes, Miaoli, Taiwan, China;
Graduate Institute of Medical Biotechnology, Chang Gung University, Tao-Yuan, Taiwan, China;
Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan, China; and
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, China
2 Correspondence: Vaccine Research and Development Center, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, China. E-mail: chenhw{at}nhri.org.tw
Cross-talk between TGF-β and IL-6 has been shown to direct the differentiation of CD4+ cells into special IL-17-secreting cells, which are termed Th17 cells. In this study, we demonstrated that TGF-β and IL-6 could stimulate CD8+ cells to differentiate into noncytotoxic, IL-17-producing cells in MLC. These IL-17-producing CD8+ cells exhibit a unique granzyme B–IFN-
–IL-10– phenotype. The mRNA level of Th2/T cytotoxic 2 (Tc2) transcription factors GATA3 and Th1/Tc1 transcription factors T-box expressed in T cell (T-bet) as well as its target H2·O-like homeobox (Hlx) is decreased in CD8+ cells from TGF-β- and IL-6-treated MLC. In addition, these CD8+ cells display a marked up-regulation of retinoic acid-related orphan receptor-
t, a key IL-17 transcription factor. These results demonstrate that the existence of an IL-17-producing CD8+ subset belongs to neither the Tc1 nor the Tc2 subset and can be categorized as a T noncytotoxic 17 (Tnc17) subset.
Key Words: IL-17 mixed lymphocyte culture cytotoxic T lymphocyte
This article has been cited by other articles:
![]() |
M. M. Curtis, S. S. Way, and C. B. Wilson IL-23 Promotes the Production of IL-17 by Antigen-Specific CD8 T Cells in the Absence of IL-12 and Type-I Interferons J. Immunol., July 1, 2009; 183(1): 381 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. McKinstry, T. M. Strutt, A. Buck, J. D. Curtis, J. P. Dibble, G. Huston, M. Tighe, H. Hamada, S. Sell, R. W. Dutton, et al. IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and Enhances Survival against High-Dose Challenge J. Immunol., June 15, 2009; 182(12): 7353 - 7363. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ciric, M. El-behi, R. Cabrera, G.-X. Zhang, and A. Rostami IL-23 Drives Pathogenic IL-17-Producing CD8+ T Cells J. Immunol., May 1, 2009; 182(9): 5296 - 5305. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Chaput, S Louafi, A Bardier, F Charlotte, J-C Vaillant, F Menegaux, M Rosenzwajg, F Lemoine, D Klatzmann, and J Taieb Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue Gut, April 1, 2009; 58(4): 520 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hamada, M. d. l. L. Garcia-Hernandez, J. B. Reome, S. K. Misra, T. M. Strutt, K. K. McKinstry, A. M. Cooper, S. L. Swain, and R. W. Dutton Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge J. Immunol., March 15, 2009; 182(6): 3469 - 3481. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Croxford, F. C. Kurschus, and A. Waisman Cutting Edge: An IL-17F-CreEYFP Reporter Mouse Allows Fate Mapping of Th17 Cells J. Immunol., February 1, 2009; 182(3): 1237 - 1241. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Burrell, K. Csencsits, G. Lu, S. Grabauskiene, and D. K. Bishop CD8+ Th17 Mediate Costimulation Blockade-Resistant Allograft Rejection in T-bet-Deficient Mice J. Immunol., September 15, 2008; 181(6): 3906 - 3914. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yi, D. Zhao, C.-L. Lin, C. Zhang, Y. Chen, I. Todorov, T. LeBon, F. Kandeel, S. Forman, and D. Zeng Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease Blood, September 1, 2008; 112(5): 2101 - 2110. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Nam, M. Terabe, M.-J. Kang, H. Chae, N. Voong, Y.-a. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, et al. Transforming Growth Factor {beta} Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17 Cancer Res., May 15, 2008; 68(10): 3915 - 3923. [Abstract] [Full Text] [PDF] |
||||